ArticleNeuroscience letters2026
Xylazine reduces methamphetamine-induced hyperlocomotion in rats through κ-opioid and α2-adrenoceptor mechanisms.
Article in Neuroscience letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Xylazine, a veterinary anesthetic, is an adulterant in fentanyl and heroin that worsens opioid-related adverse effects. Two recent evidences - one epidemiological and the other pharmacological - have emerged regarding xylazine. Epidemiologically, xylazine co-use with methamphetamine (METH) is increasing; for example, in a recent toxicology report, xylazine was detected in 30% of human METH samples. Pharmacologically, xylazine is not only an α2-adrenoceptor agonist but also a full κ-opioid receptor agonist. Here, we determined effects of xylazine (1, 2.5, 5 mg/kg) on METH (1 mg/kg)-induced hyperlocomotion and investigated α2-adrenoceptor and κ-opioid receptor mechanisms. Hyperlocomotion was selected because it is a well-characterized preclinical effect of METH. In METH-naïve rats, xylazine transiently reduced locomotor activity. For co-administration with METH, xylazine dose-dependently reduced hyperlocomotion evoked by METH. In rats pretreated with the α2-adrenoceptor antagonist yohimbine (1 mg/kg), xylazine did not reduce METH-induced hyperlocomotion. Pretreatment with the competitive κ-opioid receptor antagonist LY2456302 (30 mg/kg) also attenuated xylazine's suppression of METH-induced hyperlocomotion. In xylazine-naïve rats, neither LY2456302 (30 mg/kg) or yohimbine (1 mg/kg) affected METH-evoked hyperlocomotion or spontaneous locomotor activity. Our results show that METH-evoked hyperlocomotion is sensitive to κ-opioid and α2-adrenergic receptor activity and suggest both receptor systems contribute to xylazine's in vivo pharmacological profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.